Medscape3d
‘Take a Photograph’: Trial Shows Big Survival Gain in Advanced EGFR-Mutant NSCLC
PARIS — Final overall survival results from the phase 3 MARIPOSA study showed that the first-line amivantamab plus lazertinib combination extended overall survival notably more than osimertinib ...
National Institute for Health and Care Excellence1mon
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Yahoo Finance6d
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy (CRT) (LBA4). SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with ...
Business Insider India5y
Beware of cheap cancer drugs, they could be fakes from Bangladesh
The illegal medicine market is thriving due to their dirt cheap prices in comparison to approved drugs. Osimertinib by AstraZeneca which costs around ₹2 lakhs per dose can be bought for ₹4,500 ...